Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have been assigned an average rating of “Hold” from the twenty-one ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $388.29.
REGN has been the topic of a number of research analyst reports. Robert W. Baird upgraded Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price target on the stock in a research note on Wednesday, August 7th. Credit Suisse Group dropped their price target on Regeneron Pharmaceuticals from $333.00 to $325.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 18th. JPMorgan Chase & Co. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, June 21st. Finally, Cowen set a $349.00 price target on Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, October 8th.
In related news, major shareholder Sanofi sold 172,904 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. Insiders own 11.84% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Thor Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $32,000. Accurate Investment Solutions Inc. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $31,000. HM Payson & Co. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $31,000. Coastal Capital Group Inc. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $38,000. Finally, Focused Wealth Management Inc lifted its holdings in Regeneron Pharmaceuticals by 1,333.3% in the second quarter. Focused Wealth Management Inc now owns 129 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 120 shares during the period. 66.55% of the stock is owned by hedge funds and other institutional investors.
REGN traded up $4.67 on Monday, hitting $305.44. The company had a trading volume of 743,711 shares, compared to its average volume of 773,537. The stock has a fifty day moving average price of $286.11 and a 200-day moving average price of $315.65. Regeneron Pharmaceuticals has a 12-month low of $271.37 and a 12-month high of $442.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.11 and a current ratio of 3.88. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of 15.43, a P/E/G ratio of 1.36 and a beta of 1.14.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.60 by $0.69. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The company had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the firm earned $5.45 earnings per share. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. Analysts forecast that Regeneron Pharmaceuticals will post 18.91 EPS for the current fiscal year.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: How to Track your Portfolio in Google Finance
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.